We just have to wait to find out if he's right.
News & Analysis: Moderna INC
The company avoided a much-dreaded scenario.
Two mRNA COVID vaccines aced clinical trials. Now new virus variants are putting them to the test.
Its coronavirus vaccine isn't the only cause of investor celebration.
Both of these biotechs could be big winners in the COVID-19 vaccine market.
The company wants to see if it can still produce a sufficient response one year after inoculation.
Their winning streaks aren't over just yet.
The biotech promises that more collaborations are coming.
A coronavirus vaccine authorization, a new partnership, and a bullish revenue forecast have investors excited.